{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:42:25Z","timestamp":1785516145197,"version":"3.56.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"Dalcor Pharmaceuticals","doi-asserted-by":"publisher","award":["K23MH115812"],"award-info":[{"award-number":["K23MH115812"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"Dalcor Pharmaceuticals","doi-asserted-by":"publisher","award":["R01MH131194"],"award-info":[{"award-number":["R01MH131194"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,9,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Human T-lymphotropic virus type 1 (HTLV-1)-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP) is a chronic neurological condition characterized by progressive myelopathic symptoms including spasticity, pain, weakness, and urinary symptoms, without proven treatments. Mogamulizumab (MOG) is a monoclonal antibody that binds CCR4 and leads to the clearance of HTLV-1-infected CCR4+ cells. A phase 1-2a study in Japan evaluated MOG for the treatment of HAM\/TSP and reported decreases in HTLV-1 proviral load and neuroinflammatory markers, with clinical improvement in some participants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We administered MOG 0.1 mg\/kg every 8 weeks to individuals with HAM\/TSP as a compassionate and palliative treatment. Patients who received MOG had (1) a positive peripheral HTLV-1 antibody, (2) progressive myelopathic symptoms, and (3) a diagnosis of HAM\/TSP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Four female patients, ages 45\u201368, received MOG (range, 2\u20136 infusions) between 1 November 2019 and 30 November 2022. Two patients with &amp;lt;3 years of symptoms had milder disease, with Osame scores &amp;lt;4. The other 2, with &amp;gt;7 years of symptoms, had Osame scores &amp;gt;5. One patient, with 6 total treatments, received dose-reduced MOG after she developed a rash at the initial dose. The 2 patients with milder baseline disease reported symptomatic improvement and saw reductions in Osame and\/or modified Ashworth scale scores during follow-up. The other 2 patients showed no improvement. All 4 developed rashes after receiving MOG\u2014a treatment-limiting event in some cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Clinical trials are needed including diverse patient populations to assess the potential role of MOG for HAM\/TSP. Our findings may help inform the development of these trials.<\/jats:p><\/jats:sec>","DOI":"10.1093\/cid\/ciad281","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T06:54:04Z","timestamp":1683615244000},"page":"851-856","source":"Crossref","is-referenced-by-count":7,"title":["Mogamulizumab for Treatment of Human T-lymphotropic Virus Type 1-Associated Myelopathy\/Tropical Spastic Paraparesis: A Single-Center US-based Series"],"prefix":"10.1093","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7954-6548","authenticated-orcid":false,"given":"Eric A","family":"Meyerowitz","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Montefiore Medical Center , Bronx, New York , USA"},{"name":"Albert Einstein College of Medicine , Bronx, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shibani S","family":"Mukerji","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Neuro-Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA"},{"name":"Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Kyle Harrold","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Neuro-Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA"},{"name":"Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M","family":"Erdil","sequence":"additional","affiliation":[{"name":"Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T","family":"Chen","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Department of Dermatology, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A","family":"Rudmann","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Neuro-Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athe","family":"Tsibris","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Division of Infectious Diseases, Brigham and Women's Hospital , Boston, Massachusetts , USA"},{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagagopal","family":"Venna","sequence":"additional","affiliation":[{"name":"Division of Neuroimmunology and Neuro-Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA"},{"name":"Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory K","family":"Robbins","sequence":"additional","affiliation":[{"name":"Harvard Medical School , Boston, Massachusetts , USA"},{"name":"Division of Infectious Diseases, Massachusetts General Hospital , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"2023112721333184000_ciad281-B1","doi-asserted-by":"crossref","first-page":"15012","DOI":"10.1038\/nrdp.2015.12","article-title":"HTLV-1-associated myelopathy\/tropical spastic paraparesis","volume":"1","author":"Bangham","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2023112721333184000_ciad281-B2","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/archneur.63.11.1560","article-title":"Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study","volume":"63","author":"Olindo","year":"2006","journal-title":"Arch Neurol"},{"key":"2023112721333184000_ciad281-B3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1212\/CPJ.0000000000000832","article-title":"Management of HAM\/TSP: systematic review and consensus-based recommendations 2019","volume":"11","author":"Araujo","year":"2021","journal-title":"Neurol Clin Pract"},{"key":"2023112721333184000_ciad281-B4","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1704827","article-title":"Mogamulizumab (Anti-CCR4) in HTLV-1-associated myelopathy","volume":"378","author":"Sato","year":"2018","journal-title":"N Engl J Med"},{"key":"2023112721333184000_ciad281-B5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JOP.2017.021907","article-title":"Adult T-cell leukemia\/lymphoma","volume":"13","author":"Mehta-Shah","year":"2017","journal-title":"J Oncol Pract"},{"key":"2023112721333184000_ciad281-B6","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1177\/1060028019884863","article-title":"Mogamulizumab: an anti-CC chemokine receptor 4 antibody for T-cell lymphomas","volume":"54","author":"Moore","year":"2020","journal-title":"Ann Pharmacother"},{"key":"2023112721333184000_ciad281-B7","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/ptj\/67.2.206","article-title":"Interrater reliability of a modified Ashworth scale of muscle spasticity","volume":"67","author":"Bohannon","year":"1987","journal-title":"Phys Ther"},{"key":"2023112721333184000_ciad281-B8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1590\/S0004-282X2006000200009","article-title":"Association of cytokines, neurological disability, and disease duration in HAM\/TSP patients","volume":"64","author":"Muniz","year":"2006","journal-title":"Arquivos de neuro-psiquiatria"},{"key":"2023112721333184000_ciad281-B9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1001\/jamaoncol.2021.4318","article-title":"Management of cutaneous immune-related adverse events in patients with cancer treated with immune checkpoint inhibitors: a systematic review","volume":"8","author":"Nadelmann","year":"2022","journal-title":"JAMA Oncol"},{"key":"2023112721333184000_ciad281-B10","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1016\/j.jaip.2021.03.054","article-title":"Reintroduction of antituberculous drugs in patients with antituberculous drug-related drug reaction with eosinophilia and systemic symptoms","volume":"9","author":"Oh","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023112721333184000_ciad281-B11","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1001\/jamadermatol.2021.0877","article-title":"Clinical characterization of mogamulizumab-associated rash during treatment of mycosis fungoides or s\u00e9zary syndrome","volume":"157","author":"Hirotsu","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2023112721333184000_ciad281-B12","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciad281\/50499835\/ciad281.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/6\/851\/53845226\/ciad281.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/6\/851\/53845226\/ciad281.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T11:37:32Z","timestamp":1702381052000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/6\/851\/7157182"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,9]]},"published-print":{"date-parts":[[2023,9,18]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad281","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9,15]]},"published":{"date-parts":[[2023,5,9]]}}}